You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
JP 1302 dihydrochloride
α2C-adrenoceptor antagonist that displays ~ 50-fold selectivity over other α2-adrenoceptor subtypes (Ki values are 28, 1470, 1700 and 3150 nM for human α2C, α2B, α2D and α2A subtypes respectively). Potently antagonizes adrenalin-stimulated 35GTPγS binding in vitro (KB = 16 nM) and produces antidepressant and antipsychotic-like effects in vivo.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 441.4. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.27 mL||11.33 mL||22.66 mL|
|5 mM||0.45 mL||2.27 mL||4.53 mL|
|10 mM||0.23 mL||1.13 mL||2.27 mL|
|50 mM||0.05 mL||0.23 mL||0.45 mL|
References are publications that support the biological activity of the product.
Tricklebank (2007) JP-1302: a new tool to shed light on the roles of α2C-adrenoceptors in brain. Br.J.Pharmacol. 150 381 PMID: 17220912
Sallinen et al (2007) Pharmacological characterization and CNS effects of a novel highly selective α2C-adrenoceptor antagonist JP-1302. Br.J.Pharmacol. 150 391 PMID: 17220913
If you know of a relevant reference for JP 1302 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: JP 1302 dihydrochloride, JP 1302 dihydrochloride supplier, Potent, selective, α2C-adrenoceptor, alpha2C-adrenoceptors, α2c-adrenergic, alpha2c-adrenergic, a2c-adrenoceptor, antagonists, Receptors, JP1302, dihydrochloride, Adrenergic, Alpha-2, 2666, Tocris Bioscience
1 Citation for JP 1302 dihydrochloride
Citations are publications that use Tocris products. Selected citations for JP 1302 dihydrochloride include:
Jiang et al (2015) SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway. Mol Med Rep 18 PMID: 25522427
Do you know of a great paper that uses JP 1302 dihydrochloride from Tocris? Please let us know.
Reviews for JP 1302 dihydrochloride
There are currently no reviews for this product. Be the first to review JP 1302 dihydrochloride and earn rewards!
Have you used JP 1302 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.